Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Update

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 12,768,874 shares, a growth of 29.2% from the March 31st total of 9,884,839 shares. Approximately 18.7% of the company’s shares are short sold. Based on an average daily volume of 4,714,170 shares, the short-interest ratio is presently 2.7 days.

Inovio Pharmaceuticals Stock Down 0.4%

Shares of Inovio Pharmaceuticals stock traded down $0.01 during trading hours on Friday, reaching $1.12. 673,829 shares of the stock traded hands, compared to its average volume of 1,578,540. Inovio Pharmaceuticals has a one year low of $1.03 and a one year high of $2.98. The firm has a market capitalization of $77.42 million, a price-to-earnings ratio of -0.66 and a beta of 1.70. The company has a 50 day moving average price of $1.46 and a 200 day moving average price of $1.78.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.68. Sell-side analysts anticipate that Inovio Pharmaceuticals will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INO has been the subject of several research analyst reports. Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.75.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several large investors have recently added to or reduced their stakes in INO. AQR Capital Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 5,894 shares during the period. Qube Research & Technologies Ltd bought a new stake in Inovio Pharmaceuticals during the second quarter valued at about $234,000. Jane Street Group LLC lifted its position in shares of Inovio Pharmaceuticals by 221.2% in the second quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 27,329 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Inovio Pharmaceuticals in the third quarter worth about $27,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.